.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Deloitte
Boehringer Ingelheim
Moodys
Daiichi Sankyo
Baxter
Express Scripts
Cantor Fitzgerald
Covington

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,989,581

« Back to Dashboard

Which drugs does patent 5,989,581 protect, and when does it expire?


Patent 5,989,581 protects NUVARING and is included in one NDA. There has been one Paragraph IV challenge on Nuvaring.

This patent has thirty-two patent family members in twenty-five countries.

Summary for Patent: 5,989,581

Title: Drug delivery system for two or more active substances
Abstract:The present invention is dealing with a drug delivery system, preferably in a ring-shaped form suitable for vaginal administration, for the simultaneous release of a progestogenic steroid compound and an estrogenic steroid compound in a fixed physiological ratio over a prolonged period of time. The drug delivery system comprises at least one compartment comprising a thermoplastic polymer core containing the mixture of the progestogenic and estrogenic compounds and a thermoplastic polymer skin, the progestogenic compound being initially dissolved in the polymer core material in a relatively low degree of supersaturation.
Inventor(s): Groenewegen; Rudolf Johannes Joseph (Heesch, NL)
Assignee: Akzo Nobel N.V. (Arnhem, NL)
Application Number:09/056,700
Patent Claim Types:
see list of patent claims
Compound; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Organon Usa IncNUVARINGethinyl estradiol; etonogestrelRING;VAGINAL021187-001Oct 3, 2001RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,989,581

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
97201098Apr 11, 1997

International Patent Family for Patent: 5,989,581

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Singapore65061► Subscribe
Russian Federation2206325► Subscribe
Portugal876815► Subscribe
Poland192449► Subscribe
Poland325774► Subscribe
New Zealand330145► Subscribe
Norway320394► Subscribe
Norway981638► Subscribe
Japan2009256378► Subscribe
Japan4982670► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Novartis
AstraZeneca
Argus Health
Accenture
Federal Trade Commission
Deloitte
Healthtrust
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot